<DOC>
	<DOCNO>NCT02880293</DOCNO>
	<brief_summary>This study test whether half match donor favorable KIR gene reduce risk cancer recur transplant .</brief_summary>
	<brief_title>Haploidentical ( Half-matched ) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors Addition Normal Selection Factors Determine Best Donor</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>High risk hematologic malignancy Persons HLA match sibling donor . Female patient pregnant breastfeeding •Persons infection respond antimicrobial therapy •Persons seropositive HIV HTLV1/2 . Persons uncontrolled central nervous system malignancy •Persons meet age organ function criterion specify Presence psychiatric neurologic disease , lack social support limit patient 's ability comply treatment protocol include supportive care , followup , research test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>transplant conditioning</keyword>
	<keyword>KIR/HLA base haploidentical donor selection</keyword>
	<keyword>allogeneic hematopoietic cell transplantation</keyword>
</DOC>